Core Insights - The study from Washington University School of Medicine highlights the cardiovascular risks associated with discontinuing GLP-1 medications for Type 2 diabetes, indicating that stopping these drugs can lead to increased risks of heart attack, stroke, and death [2][3][4]. Group 1: Study Findings - The research followed over 333,000 adults with diabetes, primarily using Novo Nordisk's Ozempic, over three years [3]. - Patients who remained on GLP-1s for three years experienced an 18% reduction in cardiovascular risk [7]. - Quitting GLP-1s for as little as six months increased cardiovascular risk by 4%, while a two-year gap raised the risk to 22% compared to continuous use [7]. Group 2: Drug Benefits and Risks - GLP-1s provide significant benefits beyond weight loss, including reductions in cholesterol, blood pressure, insulin resistance, and inflammation, along with cardiovascular protection [3][4]. - The study emphasizes that the cardiovascular protection gained from GLP-1s takes years to build but can be lost in a much shorter time frame [3]. Group 3: Discontinuation Issues - High discontinuation rates for GLP-1s range from 36% to 81%, driven by access issues and side effects like nausea and vomiting [5]. - The need for long-term treatment adherence is critical, as providers and patients must recognize the consequences of stopping the medication [5][6]. - Drugmakers are working on next-generation treatments that aim to maintain efficacy while reducing side effects [8].

Core Insights - Mounjaro (tirzepatide) demonstrated non-inferiority to Trulicity (dulaglutide) in reducing major adverse cardiovascular events (MACE-3) with an 8% lower rate of such events [1][2] - Mounjaro showed a 16% reduction in all-cause mortality compared to Trulicity, indicating broader health benefits [1][2] - The SURPASS-CVOT trial is the largest and longest study of tirzepatide, involving over 13,000 participants across 30 countries [1][6] Group 1: Trial Results - Mounjaro achieved a hazard ratio of 0.92 for MACE-3 events, meeting the criteria for non-inferiority [2][3] - The trial reported a 39% reduction in all-cause mortality when comparing Mounjaro to a hypothetical placebo [2][3] - Mounjaro also showed a significant improvement in estimated glomerular filtration rate (eGFR) decline in patients with chronic kidney disease, with a treatment difference of 3.54 mL/min/1.73 m² at 36 months [2][3] Group 2: Efficacy and Safety - Mounjaro led to greater reductions in A1C levels and body weight compared to Trulicity, with a treatment difference of -0.83% in A1C and -7.1% in body weight [4][5] - The most common adverse events for both Mounjaro and Trulicity were gastrointestinal-related, with 13.3% of Mounjaro participants discontinuing treatment due to adverse events compared to 10.2% for Trulicity [5][6] - Safety profiles for both drugs were consistent with established data, indicating that Mounjaro is a viable option for patients with type 2 diabetes and cardiovascular disease [2][5]